Identification of noninvasive imaging surrogates for brain tumor gene-expression modules

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 13, 2008, Pages 5213-5218

  Diehn, Maximilian ^a,b   Nardini, Christine ^a   Wang, David S ^a   McGovern, Susan ^c   Jayaraman, Mahesh ^d   Liang, Yu ^e   Aldape, Kenneth ^c   Cha, Soonmee ^e   Kuo, Michael D ^a  

^a UCSD MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d BROWN UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; Genomics; Glioblastoma multiforme; Radiogenomics

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; CANCER SURVIVAL; CELL HYPOXIA; CELL PROLIFERATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DNA MICROARRAY; FUNCTIONAL GENOMICS; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; BRAIN TUMOR; CANCER INVASION; DIAGNOSIS, MEASUREMENT AND ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETICS; METABOLISM; PATHOLOGY; PHENOTYPE; SURVIVAL RATE; TREATMENT OUTCOME;

BRAIN NEOPLASMS; CLINICAL LABORATORY TECHNIQUES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASM INVASIVENESS; PHENOTYPE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 42449156691     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0801279105     Document Type: Article

References (34)

1. Nutt CL, et al. (2003) Gene-expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 63:1602-1607.
2. Freije WA, et al. (2004) Gene-expression profiling of gliomas strongly predicts survival. Cancer Res 64:6503-6510.
3. Liang Y, et al. (2005) Gene-expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci USA 102:5814-5819.
4. Bredel M, et al. (2005) Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res 65:8679-8689.
5. Phillips HS, et al. (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157-173.
6. Kitange GJ, Templeton KL, Jenkins RB (2003) Recent advances in the molecular genetics of primary gliomas. Curr Opin Oncol 15:197-203.
7. Mischel PS, Nelson SF, Cloughesy TF (2003) Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy. Cancer Biol Ther 2:242-247.
8. Henson JW, Gaviani P, Gonzalez RG (2005) MRI in treatment of adult gliomas. Lancet Oncol 6:167-175.
9. Rees JH, Smirniotopoulos JG, Jones RV, Wong K (1996) Glioblastoma multiforme: radiologic-pathologic correlation. Radiographics 16:1413-1438; quiz 1462-1463.
10. Aghi M, et al. (2005) Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma. Clin Cancer Res 11:8600-8605.
11. Carlson MR, et al. (2007) Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. Clin Cancer Res 13:2592-2598.
12. Earnest Ft, et al. (1988) Cerebral astrocytomas: Histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology 166:823-827.
13. Hobbs SK, et al. (2003) Magnetic resonance image-guided proteomics of human glioblastoma multiforme. J Magn Reson Imaging 18:530-536.
14. Van Meter T, et al. (2006) Microarray analysis of MRI-defined tissue samples in glioblastoma reveals differences in regional expression of therapeutic targets. Diagn Mol Pathol 15:195-205.
15. Yang YS, Guccione S, Bednarski MD (2003) Comparing genomic and histologic correlations to radiographic changes in tumors: a murine SCC VII model study. Acad Radiol 10:1165-1175.
16. Leo C, Giaccia AJ, Denko NC (2004) The hypoxic tumor microenvironment and gene-expression. Semin Radiat Oncol 14:207-214.
17. Harris AL (2002) Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2:38-47.
18. Yetkin FZ, Mendelsohn D (2002) Hypoxia imaging in brain tumors. Neuroimaging Clin N Am 12:537-552.
19. Reardon DA, Wen PY (2006) Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist 11:152-164.
20. Whitfield ML, et al. (2002) Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 13:1977-2000.
21. Halatsch ME, et al. (2006) Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat Rev 32:74-89.
22. Mellinghoff IK, et al. (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012-2024.
23. Hammoud MA, et al. (1996) Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol 27:65-73.
24. Lacroix M, et al. (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190-198.
25. Pierallini A, et al. (1998) Radiological assessment of necrosis in glioblastoma: Variability and prognostic value. Neuroradiology 40:150-153.
26. Pope WB, et al. (2005) MR imaging correlates of survival in patients with high-grade gliomas. Am J Neuroradiol 26:2466-2474.
27. Yoshizuka N, et al. (2004) An alternative transcript derived from the trio locus encodes a guanosine nucleotide exchange factor with mouse cell-transforming potential. J Biol Chem 279:43998-44004.
28. Liang F, et al. (2007) PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation. J Biol Chem 282:5413-5419.
29. Sapi E, Flick MB, Rodov S, Kacinski BM (1998) Ets-2 transdominant mutant abolishes anchorage-independent growth and macrophage colony-stimulating factor-stimulated invasion by BT20 breast carcinoma cells. Cancer Res 58:1027-1033.
30. Nutt CL, Zerillo CA, Kelly GM, Hockfield S (2001) Brain-enriched hyaluronan-binding (BEHAB)/brevican increases aggressiveness of CNS-1 gliomas in Lewis rats. Cancer Res 61:7056-7059.
31. Segal E, et al. (2007) Decoding global gene-expression programs in liver cancer by noninvasive imaging. Nat Biotechnol 25:675-680.
32. Jaffer FA, Weissleder R (2005) Molecular imaging in the clinical arena. J Am Med Assoc 293:855-862.
33. Zeeberg BR, et al. (2003) GoMiner: A resource for biological interpretation of genomic and proteomic data. Genome Biol 4:R28.
34. Aldape KD, et al. (2004) Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 63:700-707.